Literature DB >> 31271865

Crystal structure of the CTLD7 domain of human M-type phospholipase A2 receptor.

Bowen Yu1, Zhenzheng Hu1, Dandan Kong1, Chen Cheng1, Yongning He2.   

Abstract

M-type phospholipase A2 receptor (PLA2R) is a member of the mannose receptor family. Recent evidence shows that PLA2R is a major autoantigen causing idiopathic membranous nephropathy (IMN), which is an autoimmune disease and one of the most common causes for nephrotic syndrome in adults. The epitope mapping data suggest that the major epitopes of PLA2R locate at the CysR, CTLD1 and CTLD7 domains. However, due to the lack of the high-resolution structural information, it is unclear how the autoantibodies interact with PLA2R. Here we determine the crystal structure of the CTLD7 domain of PLA2R at 1.8 Å, showing that it adopts a typical CTLD fold, and the structural alignments also provide hints for the potential antibody binding regions. In addition, the high-resolution structural information of CTLD7 could be applied to identify the epitopes for autoantibodies, which would facilitate the therapeutic strategies against IMN.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CTLD7; Idiopathic membranous nephropathy; Mannose receptor family; PLA2R

Mesh:

Substances:

Year:  2019        PMID: 31271865     DOI: 10.1016/j.jsb.2019.06.007

Source DB:  PubMed          Journal:  J Struct Biol        ISSN: 1047-8477            Impact factor:   2.867


  2 in total

1.  Refining Our Understanding of the PLA2R-Antibody Response in Primary Membranous Nephropathy: Looking Forward, Looking Back.

Authors:  Laurence H Beck; David J Salant
Journal:  J Am Soc Nephrol       Date:  2019-12-16       Impact factor: 10.121

2.  Structure of PLA2R reveals presentation of the dominant membranous nephropathy epitope and an immunogenic patch.

Authors:  Maryline Fresquet; Michael P Lockhart-Cairns; Samuel J Rhoden; Thomas A Jowitt; David C Briggs; Clair Baldock; Paul E Brenchley; Rachel Lennon
Journal:  Proc Natl Acad Sci U S A       Date:  2022-07-11       Impact factor: 12.779

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.